The 13-Valent Pneumococcal Conjugate Vaccine (PCV13) represents one of the most significant breakthroughs in pediatric and geriatric immunology. As a professional supplier, Jiangxi Serum Pharma Industries Co., Ltd. recognizes that the wholesale distribution of PCV13 is not merely a commercial transaction but a critical public health mission. PCV13 targets 13 distinct serotypes of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), which are responsible for the majority of invasive pneumococcal diseases (IPD) globally.
By utilizing the CRM197 carrier protein, PCV13 induces a T-cell dependent immune response, which is crucial for establishing long-term immunological memory in infants—a feat that older polysaccharide vaccines could not achieve. Our wholesale services ensure that these life-saving biological products reach high-demand markets with uncompromised potency.
Established in 2017, Jiangxi Serum Pharma Industries Co., Ltd. has spent nearly a decade perfecting the export of biological products and Western medicines from China. With annual sales exceeding $10M USD, we serve as a bridge between high-quality Chinese manufacturing and global healthcare needs.
Serotypes Protected
Reduction in IPD
Foundation Year
Annual Sales (USD)
The global PCV market is projected to reach billions in value by 2030. Currently, PCV13 remains the "Gold Standard" for national immunization programs (NIPs) across Asia, Africa, and Latin America due to its proven efficacy and established safety profile.
China has emerged as a powerhouse in vaccine manufacturing. With the domestic development of PCV13, the monopoly of Western pharmaceutical giants has been challenged, allowing for more competitive wholesale pricing for emerging markets.
We focus on products that align with WHO Prequalification standards, ensuring that our wholesale vaccine services meet the rigorous quality requirements of international NGOs and government procurement agencies.
Individual cultivation of 13 serotypes under strict bioreactor conditions to ensure high-yield capsular polysaccharide production.
Advanced chromatography ensures 99%+ purity. The polysaccharides are then chemically activated to prepare for conjugation with the carrier protein.
The core technology where the weak antigen (polysaccharide) is bound to the CRM197 protein, transforming it into a potent immunogen capable of stimulating memory B-cells.
Final formulation with aluminum phosphate adjuvants to enhance the immune response, followed by aseptic filling into pre-filled syringes or vials.
Wholesale distribution of the 13-Valent Pneumonia Vaccine requires more than just logistics; it requires a Macro Industry Solution that integrates regulatory support, cold chain integrity, and localized market insights.
We implement real-time temperature monitoring for every shipment. Our vaccines are transported in validated passive cooling systems or active refrigerated units to prevent protein denaturation.
We provide comprehensive CTD (Common Technical Document) dossiers to assist our partners in local registration with national health authorities (FDA, EMA, or local MOH).
Jiangxi Serum Pharma supports partners in bidding for government tenders, providing the necessary documentation and competitive wholesale pricing structures needed to win large-scale contracts.
Serum Pharma continuously monitors cutting-edge market developments. Beyond vaccines, we are expanding our industrial capabilities to support our partners through specialized services:
Customized formulation blends for nutritional and pharmaceutical applications.
Enhancing the solubility and stability of active pharmaceutical ingredients (APIs).
Advanced microbial fermentation for producing complex biological molecules and proteins.
In many developing nations, the introduction of PCV13 into the NIP is the single most effective way to reduce child mortality rates. We facilitate bulk supply for state-level health departments.
High-end private medical facilities require consistent, high-quality stock of PCV13 to cater to health-conscious urban populations. Our wholesale service provides flexible volume options.
With an aging global population, the use of PCV13 for adults over 65 is increasing. We help distributors tap into this growing segment of "Active Aging" products.
Pneumonia often surges in refugee camps or disaster zones. We offer rapid-response supply chains for humanitarian organizations requiring large quantities of vaccines quickly.
While PCV13 is the current standard, the industry is moving toward even broader coverage. At Jiangxi Serum Pharma, we are tracking these trends to keep our clients ahead of the curve.
The next generation of vaccines is adding serotypes 22F and 33F (PCV15) or even more (PCV20). We are building partnerships to secure early access to these developments.
Post-COVID, mRNA research is pivoting toward multi-valent bacterial vaccines. This could revolutionize how quickly we adapt to "Serotype Replacement" trends.
As manufacturing processes become more efficient, we anticipate a decrease in the cost-per-dose, making the 13-valent vaccine accessible to even the most remote regions.
